about
What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Statins impair glucose uptake in tumor cellsColorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism.Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.Dosimetry in clinical radionuclide therapy: the devil is in the detail.Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA.Correction to: Dosimetry in clinical radionuclide therapy: the devil is in the detail.A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy.Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions - own experience.Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.Radioguided surgery in patient with pancreatic neuroendocrine tumour followed by PET/CT scan as a new approach of complete resection evaluation--case report.Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).Jak często wykrywamy przypadkowe zmiany w tarczycy w badaniu PET/CT z 68Ga-DOTATATE u pacjentów diagnozowanych z powodu nowotworu neuroendokrynnego?Nietypowy przypadek przebiegu nowotworu neuroendokrynnego trzustki pod postacią przerzutu do serca — opis przypadku klinicznegoRadioiodine therapy in patients with type II amiodarone‑induced thyrotoxicosisRetroperitoneal Pheochromocytoma With Thorax and Bilateral Neck Chemodectoma in Patients With Multiorgan SarcoidosisPolish Experience in Peptide Receptor Radionuclide TherapyRepeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NETTumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-61768Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience - do we need [18Liver transplantation as an option of treatment for a giant primary hepatic neuroendocrine tumourTandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experienceSafety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
P50
Q34484987-CBE9BA71-88D8-4A41-A116-F1A037DDA2F7Q35201583-DA689768-2B86-4764-AD65-FE2143F6F12FQ35949773-326E490F-F268-4B2C-8023-EB5895563984Q38178906-0D38CA11-40B7-453B-B543-520DEAC61275Q38765743-29080733-5D87-4238-A637-B63E55C20C09Q40186992-6D501566-09D5-40C8-A08F-F733240BF6F2Q44656493-46F7AB80-4485-4852-9F6E-48393EF59A5AQ44661227-E35BD61E-D7F0-4DB1-967C-D3AA4FA00BD0Q46954744-4B88EC04-2F7F-4209-AA08-9FE3A643213BQ47574245-D135AB57-BBA6-463F-B08D-5BE2E7E8202EQ48089118-6B4A0103-0229-431C-82BF-8CDB9A9CFDB0Q48097399-7DAB96DC-88E6-4EBC-B933-47F5F0A26EDDQ48152224-F6697232-C8D9-40B8-96DC-FBC5419B73C2Q48265621-C3214976-9AFD-4525-B027-7B28A0EA65BBQ48630857-F45D4DA5-6F4A-41BA-A55C-ABCED92AC8DBQ49506151-40F9BA5F-D1A2-4B86-B14F-FD005DEBDA59Q50095193-D98D1BAD-2221-44DC-B304-B8C218A04B8BQ50690655-E931CBCE-58EA-455B-95C5-0E0DB98B8BF3Q50790805-F91D4F99-7486-4EF2-9E4A-302E8FA41292Q52715248-5D6472D5-7EAC-4AAC-86C1-89403AE37F8AQ52984876-97F38D2E-4CF9-4D38-96B0-A8B114E56215Q53057730-03C59ECC-6F5B-41BC-8233-E6037B323AA8Q53269901-196A3951-D20E-426B-98C1-16DD4AAF9B4EQ53962002-2A15DC18-8E41-4B22-B3B0-5FF4897CAC48Q54344626-35BA46AF-0139-4B13-B3C8-252C6E24DB6EQ57967391-7E8DDA21-7313-40B1-A555-34928F0813ACQ57967403-BB335932-7A2E-4D9F-9D94-CC90A17DDA73Q57967410-EBF8E7E8-FA00-41EA-9050-E0CA1829B99CQ57967414-E76F5163-5334-43FC-985A-54CDE23530E3Q57967441-53E64DF3-61BE-4C06-8DEA-2DE6D36CFD8AQ57967463-CF40B7BE-39E5-46FB-992A-912819F396BDQ89629568-1F3CF528-D150-435F-8D56-C4FD87B1AD23Q89677562-36103254-8C1C-49FE-88EA-F33A61B516F3Q90998342-26E82F72-959C-4E6A-AE06-0ADCB598DD0CQ91952805-3DC4D108-9B94-45A3-9C92-75C8B24820E7Q92466986-CA90BB4E-0D04-4523-A94D-A68D4849516FQ92933852-C403192D-7F96-49CF-A282-125A57C0CCD9Q93380708-23DA9879-0C9D-4A37-BD4A-0E08930AC855
P50
description
Pools onderzoekster
@nl
cercetătoare poloneză
@ro
chercheuse polonaise
@fr
hulumtuese
@sq
investigadora polaca
@ast
investigadora polaca
@es
investigadora polaca
@gl
investigadora polonesa
@ca
polnische Forscherin
@de
polska naukowiec
@pl
name
Jolanta Kunikowska
@ast
Jolanta Kunikowska
@ca
Jolanta Kunikowska
@de
Jolanta Kunikowska
@en
Jolanta Kunikowska
@es
Jolanta Kunikowska
@fr
Jolanta Kunikowska
@ga
Jolanta Kunikowska
@gl
Jolanta Kunikowska
@it
Jolanta Kunikowska
@nl
type
label
Jolanta Kunikowska
@ast
Jolanta Kunikowska
@ca
Jolanta Kunikowska
@de
Jolanta Kunikowska
@en
Jolanta Kunikowska
@es
Jolanta Kunikowska
@fr
Jolanta Kunikowska
@ga
Jolanta Kunikowska
@gl
Jolanta Kunikowska
@it
Jolanta Kunikowska
@nl
prefLabel
Jolanta Kunikowska
@ast
Jolanta Kunikowska
@ca
Jolanta Kunikowska
@de
Jolanta Kunikowska
@en
Jolanta Kunikowska
@es
Jolanta Kunikowska
@fr
Jolanta Kunikowska
@ga
Jolanta Kunikowska
@gl
Jolanta Kunikowska
@it
Jolanta Kunikowska
@nl
P214
P1053
M-3625-2018
P106
P1153
24073411800
P1412
P1559
Jolanta Kunikowska
@pl
P21
P214
P27
P31
P496
0000-0002-7434-6720
P735
P7859
viaf-291009802